Kim, Hyung Suk <br/><br/>
The prognostic value of HER2 status and efficacy of anti-HER2 therapy in patients with HR-positive mucinous breast cancer: a nationwide study from the Korean Breast Cancer Society.  [electronic resource] 

 -  Breast cancer research and treatment  Apr 2020 
 - 461-470 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1573-7217 
<br/><br/><label>Standard No.: </label>10.1007/s10549-020-05550-4  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma, Mucinous--drug therapy<br/>Antineoplastic Agents, Immunological--therapeutic use<br/>Breast Neoplasms--drug therapy<br/>Chemotherapy, Adjuvant--methods<br/>Estrogen Receptor alpha--metabolism<br/>Female<br/>Humans<br/>Middle Aged<br/>Prognosis<br/>Receptor, ErbB-2--antagonists & inhibitors<br/>Receptors, Progesterone--metabolism<br/>Republic of Korea<br/>Societies, Medical<br/>Survival Rate<br/>Trastuzumab--therapeutic use